Compare BridgeBio Pharma Inc (BBIO) vs International Business Machines Corp (IBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs International Business Machines Corp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while International Business Machines Corp trades at $238.2 (market cap $222.64B). The key difference: International Business Machines Corp is far larger — about 13.4× BridgeBio Pharma Inc's market cap, and International Business Machines Corp pays a 2.86% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | IBM | |
|---|---|---|
Market Cap | $16.61B | $222.64B |
Sector | Health | Technology |
52-Week High | $90.17 | $329.23 |
52-Week Low | $47.29 | $205.77 |
Enterprise Value | $18.16B | $279.78B |
Volume | — | 4,481,527 |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
IBM trades at $237.28, up 1.65% today, with a mixed technical outlook showing bullish overall signals but bearish momentum indicators. Recent earnings beat expectations in Q1 2026, though Q2 2026 matched estimates, and revenue growth accelerated to $67.54 billion in 2025. The company maintains strong profitability with a net income margin of 15.52% and a dividend yield of approximately 2.8%, supported by positive cash flow from operations of $13.19 billion.
The stock offers a balanced risk-reward profile, with a consensus price target of $257.38 implying 8.5% upside, but faces headwinds from a securities fraud investigation and competitive pressures in AI. Long-term growth hinges on quantum computing and hybrid cloud adoption, yet near-term volatility may persist due to legal uncertainties and macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →
